Skip to main content

Advertisement

SpringerLink
Log in

Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

The present study compared the complications associated with hypofractionated intensity-modulated radiation therapy (Hypo-IMRT) of prostate cancer to conventionally fractionated IMRT (Conv-IMRT).

Materials and methods

Hypo-IMRT delivered 70 Gy in 28 fractions, whereas Conv-IMRT delivered 78 Gy in 39 fractions. Toxicity was graded with the Common Terminology Criteria for Adverse Events, version 4.0, weekly during radiotherapy, 1 month after radiotherapy, and annually in both patient groups.

Results

The median follow-ups were 39.1 and 38.7 months for patients in the Hypo- and Conv-IMRT groups, respectively. There was no significant difference in rates of acute and late adverse events. The proportions of grade 2 acute genitourinary complications were 48.4 and 51.2% in the Hypo- and Conv-IMRT groups, respectively. The presence of a baseline International Prostate Symptom Score (IPSS) of ten or more was the only significant prognostic factor for grade 2 acute genitourinary toxicity. The incidence of grade 2 late rectal hemorrhage at 3 years was 3.2 and 3.5% in the Hypo- and Conv-IMRT groups, respectively. Small rectal volume was significantly associated with grade 2 late rectal hemorrhage.

Conclusion

Regarding acute and late adverse events, hypofractionated IMRT for prostate cancer was well tolerated and comparable with conventionally fractionated IMRT.

Clinical trial registration no. UMIN000003218.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.

    Article  PubMed  Google Scholar 

  2. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;28(7):1106–11.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–8.

    Article  PubMed  Google Scholar 

  4. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–87.

    Article  PubMed  Google Scholar 

  5. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63.

    Article  PubMed  Google Scholar 

  6. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009;74(5):1405–18.

    Article  PubMed  Google Scholar 

  7. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124–9.

    Article  PubMed  Google Scholar 

  8. Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA J Am Med Assoc. 2013;309(24):2587–95.

    Article  CAS  Google Scholar 

  9. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Miller DC, et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol. 2014;65(1):162–8.

    Article  PubMed  Google Scholar 

  10. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43(5):1095–101.

    Article  CAS  PubMed  Google Scholar 

  11. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta oncologica. 2005;44(3):265–76 (Stockholm, Sweden).

    Article  PubMed  Google Scholar 

  12. Miles EF, Lee WR. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol. 2008;18(1):41–7.

    Article  PubMed  Google Scholar 

  13. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. 2013;85(1):89–94.

    Article  PubMed  Google Scholar 

  14. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424–30.

    Article  PubMed  Google Scholar 

  15. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;69(4):1084–9.

    Article  PubMed  Google Scholar 

  16. Rene N, Faria S, Cury F, David M, Duclos M, Shenouda G, et al. Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77(3):805–10.

    Article  PubMed  Google Scholar 

  17. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11–8.

    Article  PubMed  Google Scholar 

  18. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaro P, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1172–8.

    Article  PubMed  Google Scholar 

  19. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13(1):43–54.

    Article  PubMed  Google Scholar 

  20. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys. 1999;43(3):475–9.

    Article  CAS  PubMed  Google Scholar 

  22. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrun S, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47(1):103–13.

    Article  CAS  PubMed  Google Scholar 

  23. Akimoto T, Muramatsu H, Takahashi M, Saito J, Kitamoto Y, Harashima K, et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2004;60(4):1033–9.

    Article  PubMed  Google Scholar 

  24. Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys. 2010;76(3):755–60.

    Article  PubMed  Google Scholar 

  25. Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70(4):1130–7.

    Article  PubMed  Google Scholar 

  26. Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys. 2011;79(1):195–201.

    Article  PubMed  Google Scholar 

  27. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82(1):e17–24.

    Article  PubMed  Google Scholar 

  28. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50(4):1021–31.

    Article  CAS  PubMed  Google Scholar 

  29. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61(4):1019–34.

    Article  PubMed  Google Scholar 

  30. Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, et al. Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study. Int J Radiat Oncol Biol Phys. 2007;67(5):1401–10.

    Article  PubMed  Google Scholar 

  31. Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol. 2001;59(1):65–70.

    Article  CAS  PubMed  Google Scholar 

  32. Fiorino C, Cozzarini C, Vavassori V, Sanguineti G, Bianchi C, Cattaneo GM, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol. 2002;64(1):1–12.

    Article  PubMed  Google Scholar 

  33. Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 1998;41(1):83–92.

    Article  CAS  PubMed  Google Scholar 

  34. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48(3):635–42.

    Article  CAS  PubMed  Google Scholar 

  35. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(4):904–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the assistance of Yuko Ohtomo and other members of the Department of Radiation Oncology at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. This work was supported by Health and Labour Sciences Research Grants (H26-Cancer Policy-General-014).

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Takuyo Kozuka, Keiko Nemoto Murofushi, Minako Sumi & Masahiko Oguchi

  2. Department of Physics, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan

    Masahiro Nakano & Masatoshi Hashimoto

  3. Department of Radiation Oncology, Japanese Red Cross Society Suwa Hospital, Nagano, Japan

    Kotaro Gomi

  4. Department of Urology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

    Junji Yonese

Authors
  1. Takuyo Kozuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masatoshi Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kotaro Gomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keiko Nemoto Murofushi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Minako Sumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Junji Yonese
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahiko Oguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takuyo Kozuka.

Ethics declarations

Conflict of interest

This study was funded by Health and Labour Sciences Research Grants (H26-Cancer Policy-General-014).

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kozuka, T., Nakano, M., Hashimoto, M. et al. Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer. Jpn J Radiol 35, 269–278 (2017). https://doi.org/10.1007/s11604-017-0630-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-017-0630-2

Keywords

Search

Navigation